<div id="readability-page-1"><ul><li>Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026</li></ul><p>Eli Lilly and Company, Pfizer, Novo Nordisk A/S, Abbott Laboratories,  and AbbVie are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies that research, develop, manufacture, and sell prescription drugs and vaccines. Investors evaluate them based on drug pipelines, clinical trial and regulatory outcomes, patent protection, pricing and reimbursement risks, and are prepared for potentially high volatility driven by binary events like approvals or trial failures. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.</p><div><p><span></span><span>Get <strong>Eli Lilly and Company</strong> alerts:</span></p></div><h2>Eli Lilly and Company (LLY)</h2><p>Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.</p><ul><li>Sector Rotation: 2 Smart Money Moves for 2026</li></ul><p>Read Our Latest Research Report on LLY</p><h2>Pfizer (PFE)</h2><p>Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Read Our Latest Research Report on PFE</p><h2>Novo Nordisk A/S (NVO)</h2><p>Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.</p><p>Read Our Latest Research Report on NVO</p><h2>Abbott Laboratories (ABT)</h2><p>Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.</p><p>Read Our Latest Research Report on ABT</p><h2>AbbVie (ABBV)</h2><p>AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.</p><p>Read Our Latest Research Report on ABBV</p><h2>See Also</h2><ul><li>MarketBeat's Top Five Stocks to Own in December 2025</li><li>DraftKings Launches Prediction Markets: Analysts Eye 30% Upside</li><li>A Christmas Stress Test: Why Diesel Pricing Stress Means Profits</li><li>MarketBeat’s Top-Rated Dividend Stocks for 2026</li><li>Why This Small Cap Mining Stock Surged 1,000%+ in 2025</li><li>Why Platinum May Catch Up to Gold in 2026—And How to Get Exposure</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p><p>While Eli Lilly and Company currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ABBV

<p>Eli Lilly, Pfizer, Novo Nordisk, Abbott Laboratories, and AbbVie are highlighted as promising pharmaceutical stocks to watch, according to MarketBeat. These companies are evaluated based on their drug pipelines and clinical outcomes, with potential for high volatility due to regulatory events. Eli Lilly offers various diabetes and obesity treatments, while Pfizer focuses on biopharmaceuticals across multiple therapeutic areas. Novo Nordisk specializes in diabetes and rare diseases, Abbott provides a range of healthcare products, and AbbVie develops treatments for autoimmune diseases and cancers. Investors are advised to monitor these stocks closely.</p>

- Pharmaceutical stocks, including Eli Lilly, Pfizer, Novo Nordisk, Abbott, and AbbVie, are highlighted as high-volume stocks to monitor.  
- Investors assess these companies based on drug pipelines and regulatory outcomes, anticipating volatility from approvals or failures.  
- Eli Lilly has a portfolio of diabetes and obesity treatments, while other companies offer various biopharmaceutical products across multiple therapeutic areas.

Promising Pharmaceutical Stocks To Add to Your Watchlist - December 30th